EQS-Adhoc: Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusionEQS
Im Artikel erwähnte Wertpapiere: Kuros Bioscienc N
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Patent
Schlieren (Zurich), Switzerland, May 5, 2021 - Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled 'Pharmaceutical Formulation for Use in Spinal Fusion'. This patent claims certain matrix materials in combination with parathyroid hormone (PTH) or derivatives of PTH.
This patent strengthens the intellectual property around Fibrin-PTH, Kuros's drug-biologic combination product for bone generation. Fibrin-PTH (KUR-113) has recently entered a Phase 2 clinical study in spinal fusion and is recruiting patients at multiple sites in the U.S.
Joost de Bruijn, Chief Executive Officer of Kuros, said: 'Adding this patent to our broad intellectual property portfolio further reinforces Kuros's position as a leader in the field of orthobiologics. We look forward to bringing our Fibrin-PTH product candidate (KUR-113) to market and to expanding the number of patients benefiting from our products.'
For further information, please contact:
About Fibrin-PTH (KUR-113)
About Kuros Biosciences AG
Forward Looking Statements
End of ad hoc announcement
|Company:||Kuros Biosciences AG|
|Phone:||+41 44 733 4747|
|Fax:||+41 44 733 4740|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1192536|
|End of Announcement||EQS Group News Service|
1192536 05-May-2021 CET/CEST